Trial Profile

A phase 1 clinical study evaluating STI-1558 in subjects with COVID-19

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olgotrelvir (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

23 Aug 2022 New trial record
19 Aug 2022 According to Sorrento Therapeutics media release, Dr. Lu Hangzhou is leading the trial in China.
19 Aug 2022 According to Sorrento Therapeutics media release, the trial will support seeking approval for an Emergency Use Authorization (EUA) in China and will be conducted by ACEA Therapeutics, Inc., a Sorrento company, and the Third Shenzhen Hospital in Shenzhen China.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com